BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib

BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib

BackgroundAbout 15% of Triple-Negative-Breast-Cancer (TNBC) present silencing of the BRCA1 promoter methylation and are assumed to be Homologous Recombination Deficient (HRD). BRCA1-methylated (BRCA1-Me) TNBC could, thus, be eligible to treatment based on PARP-inhibitors or Platinum salts. However,...

Full description

Bibliographic Details
Main Authors: Carolina Velazquez, Esin Orhan, Imene Tabet, Lise Fenou, Béatrice Orsetti, José Adélaïde, Arnaud Guille, Simon Thézénas, Evelyne Crapez, Pierre-Emmanuel Colombo, Max Chaffanet, Daniel Birnbaum, Claude Sardet, William Jacot, Charles Theillet
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Oncology
Subjects:
TNBC
BRCA1 methylation
RAD51
nuclear foci
HRD (homologous recombination deficiency)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1125021/full

Similar Items

Similar Items